Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6536
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies ; volume:9 ; number:2 ; day:18 ; month:9 ; year:2020 ; pages:317-333 ; date:12.2020
Neurology and Therapy ; 9, Heft 2 (18.9.2020), 317-333, 12.2020
- Creator
-
Koike, Haruki
Katsuno, Masahisa
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40120-020-00210-7
- URN
-
urn:nbn:de:101:1-2020121519402709564179
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Koike, Haruki
- Katsuno, Masahisa
- SpringerLink (Online service)
Other Objects (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
Hereditary transthyretin amyloidosis overview
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Multidisciplinary Approaches for Transthyretin Amyloidosis
Sex differences in transthyretin cardiac amyloidosis
Hereditary transthyretin amyloidosis: a case report
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Current Disease-Modifying Therapies in Multiple Sclerosis
Hereditary transthyretin amyloidosis overview
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Multidisciplinary Approaches for Transthyretin Amyloidosis
Sex differences in transthyretin cardiac amyloidosis
Hereditary transthyretin amyloidosis: a case report
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Current Disease-Modifying Therapies in Multiple Sclerosis
Hereditary transthyretin amyloidosis overview
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Multidisciplinary Approaches for Transthyretin Amyloidosis
Sex differences in transthyretin cardiac amyloidosis
Hereditary transthyretin amyloidosis: a case report
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register